Impact of immunotherapy with pseudomonas serotip xv etanolic extract (Cantastim) on local recurrence and survival at 3 and 5 years in operated rectal cancer

Although most recurrences (approximately 80%) occur in the first three years after a curative resection, a recurrence of CRC can occur even ten years after the initial curative resection (dormant spread of cancer cells). Immunotherapy is an emerging therapy with high potential. The immune system plays a major role in the development of CRC. This has led to innovative new therapies, such as cancer vaccines and T-cell stimulation therapies. Cantastim belongs to the class of nonspecific immunostimulators or immunomodulators, most of which are of bacterial origin and are used as mono- or polymicrobial suspensions. Cantastim is an ethanolic extract obtained from a pathogenic strain of Pseudomonas aeruginosa serotype XV. The beneficial effect of immunotherapy with Cantastim was more pronounced for the local developmental stages (I and II) than for the later stages